Milestone Pharmaceuticals Inc MIST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MIST is a good fit for your portfolio.
News
-
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
-
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
-
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
-
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
-
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
-
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
-
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
-
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
Trading Information
- Previous Close Price
- $1.63
- Day Range
- $1.61–1.70
- 52-Week Range
- $1.33–4.49
- Bid/Ask
- $1.58 / $1.69
- Market Cap
- $87.17 Mil
- Volume/Avg
- 29,523 / 352,801
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 70.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 47
- Website
- https://www.milestonepharma.com
Comparables
Valuation
|
Metric
|
MIST
|
CRNX
|
TLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 107.16 |
Price/Book Value | — | 5.44 | 29.59 |
Price/Sales | 70.02 | 622.39 | 8.75 |
Price/Cash Flow | — | — | 181.88 |
Price/Earnings
MIST
CRNX
TLX
Financial Strength
|
Metric
|
MIST
|
CRNX
|
TLX
|
|---|---|---|---|
Quick Ratio | 9.67 | 12.92 | 1.19 |
Current Ratio | 10.11 | 13.07 | 1.43 |
Interest Coverage | −23.92 | — | 1.15 |
Quick Ratio
MIST
CRNX
TLX
Profitability
|
Metric
|
MIST
|
CRNX
|
TLX
|
|---|---|---|---|
Return on Assets (Normalized) | −56.36% | −38.81% | 3.71% |
Return on Equity (Normalized) | — | −44.79% | 11.73% |
Return on Invested Capital (Normalized) | −62.69% | −45.62% | 18.08% |
Return on Assets
MIST
CRNX
TLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lgznsrqc | Nmkd | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vzzrpydp | Qgwhjk | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vxwycrvh | Vszrtf | $98.1 Bil | |
MRNA
| Moderna Inc | Rlqyrkvc | Hykp | $39.1 Bil | |
ARGX
| argenx SE ADR | Rgbqlrsk | Mrb | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Ygbcpvvb | Skmb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mghqyngf | Mkgpkj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ygmlbcjzw | Lcfvqq | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tpzgmbjfc | Wtsnlh | $12.5 Bil | |
INCY
| Incyte Corp | Ldzxnvynf | Vcjnxg | $11.9 Bil |